title: Effect of ecabet sodium treatment on urea breath test and stool antigen tests in volunteers with Helicobacter pylori infection.
abstract: OBJECTIVE
  Ecabet sodium is reported to have a bactericidal effect on Helicobacter pylori and inhibit urease activity in vitro.
  
  
  METHODS
  Seven male volunteers (mean age, 51.3 years; range, 45-55 years) with H. pylori infection were medicated with 1 g ecabet sodium t.i.d. for 4 weeks. The urea breath test (UBT) was performed 10 times per person: before medication, seven times in 2 weeks, and once in the third and fourth weeks. Stool antigen tests (HpSA PLUS and Testmate pylori antigen) were performed five times per person: before medication and weekly during medication.
  
  
  RESULTS
  The premedication UBT value ranged from 4.9 ‰ to 77.4 ‰ and from 2.9 ‰ to 44 ‰ at the end of the treatment period. Not one of the subjects had a negative UBT result during medication. The optical densities of the HpSA and Testmate pylori antigen tests ranged from 0.4 to > 3.0 premedication and from 0.0 to > 3.0 at the end of treatment. HpSA and Testmate pylori antigen were negative in two cases.
  
  
  CONCLUSIONS
  In this study, ecabet sodium did not effect the results of UBT in volunteers with H. pylori infection. Ecabet sodium may influence stool antigens because in two of seven cases the H. pylori stool antigen tests returned negative results.
authors.affiliation: Department of General Medicine and Community Health Science, Sasayama Medical Center, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. okuda@naxnet.or.jp
authors.forename: Masumi
authors.initials: M
authors.lastname: Okuda
authors.forename: Noriyasu
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Fukuda
authors.forename: Kohei
authors.initials: K
authors.lastname: Maekawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kusaka
authors.forename: Manabu
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Junichiro
authors.initials: J
authors.lastname: Kotake
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Koizuka
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fukuda
mesh_terms: D045784:Abietanes / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000032:analysis*; D001944:Breath Tests; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000382:microbiology; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D013997:Time Factors; D016896:Treatment Outcome; D014508:Urea / Q000378:metabolism*; D014510:Urease / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D045784:Abietanes; D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; C061681:ecabet; D014508:Urea; D014510:Urease